Sign In
Buy OMER
$10.01
-0.270 (-2.63%)
At Close: Jul 13, 2026
Omeros Corporation Investigated by the Portnoy Law Firm
02:16pm, Monday, 13'th Jul 2026
LOS ANGELES, July 13, 2026 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Omeros Corporation , (“ Omeros " or the "Company") ( NASDAQ : OMER ) investors that the firm has initiated an investigatio
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Omeros Corporation - OMER
07:57pm, Thursday, 09'th Jul 2026
NEW YORK, July 9, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Omeros Corporation ("Omeros" or the "Company") (NASDAQ: OMER). Such investors are advised to cont
Heartflow vs. Omeros: Which Healthcare Innovator Stock Is a Better Buy in 2026?
05:21pm, Wednesday, 08'th Jul 2026
Heartflow uses artificial intelligence to transform coronary imaging into actionable diagnostic data for heart disease. Omeros is launching its first commercial product, Yartemlea, while maintaining a
OMER Investors Have Opportunity to Join Omeros Corporation Fraud Investigation with the Schall Law Firm
09:34am, Wednesday, 08'th Jul 2026
LOS ANGELES, July 08, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Omeros Corporatio
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Omeros Corporation - OMER
05:47pm, Tuesday, 07'th Jul 2026
NEW YORK, July 07, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Omeros Corporation (“Omeros” or the “Company”) (NASDAQ: OMER). Such investors are ad
OMER Investors Have Opportunity to Join Omeros Corporation Fraud Investigation with the Schall Law Firm
07:57pm, Monday, 06'th Jul 2026
LOS ANGELES--(BUSINESS WIRE)---- $OMER--OMER Investors Have Opportunity to Join Omeros Corporation Fraud Investigation with the Schall Law Firm.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Omeros Corporation - OMER
08:11pm, Wednesday, 01'st Jul 2026
NEW YORK, July 1, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Omeros Corporation ("Omeros" or the "Company") (NASDAQ: OMER). Such investors are advised to cont
Omeros stock crashes on regulatory setback: buy the dip?
02:11pm, Friday, 26'th Jun 2026
Omeros Corp (OMER) stock is tumbling on Friday morning following a major regulatory setback in Europe that has caught investors off guard. Investors are bailing on OMER mostly because the European Med
FDA Approved, Europe Unconvinced: Omeros' Stem Cell Transplant Treatment Hits Regulatory Divide
11:16am, Friday, 26'th Jun 2026
The European Medicines Agency's Human Medicines Committee (CHMP) on Friday issued a negative opinion for Omeros Corp.'s (NASDAQ:OMER) narsoplimab.
Omeros Corporation Announces Update on European Marketing Authorization Application for Narsoplimab in TA-TMA
08:30am, Friday, 26'th Jun 2026
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) announced today an update on the review by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA)
NovoCure vs. Omeros: Which Emerging Pharmaceutical Stock Is a Better Buy in 2026?
10:39am, Monday, 22'nd Jun 2026
Both companies target serious health challenges, but their financials and risk profiles reveal sharply different paths for growth-focused investors.
Intellia Therapeutics vs. Omeros: Which Emerging Biotech Stock Is a Better Buy in 2026?
11:02am, Saturday, 20'th Jun 2026
Intellia Therapeutics is leveraging its strategic partnership with Regeneron to advance a deep pipeline of CRISPR-based gene editing therapies. Omeros recently entered the commercial stage with the FD
Omeros Announces Webcast Details for Annual Meeting of Shareholders
08:30am, Monday, 15'th Jun 2026
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced that the company will host a live webcast of its Annual Meeting of Shareholders, which will be held virtually on Thursday, J
Bears are Losing Control Over Omeros (OMER), Here's Why It's a 'Buy' Now
10:56am, Thursday, 04'th Jun 2026
Omeros (OMER) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall St
Omeros Q1 Earnings Call Highlights
12:15am, Thursday, 14'th May 2026
Omeros NASDAQ: OMER reported first-quarter 2026 net income of $56.1 million, or $0.78 per share, as the company began commercial sales of YARTEMLEA, its recently approved treatment for hematopoietic s
